Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been associated with lower atrial fibrillation (AF) incidence in diabetes mellitus (DM). Atrial electromechanical delay (AEMD) is an electrophysiological marker related to AF development. This study evaluated AEMD changes in type 2 DM patients treated with an SGLT2 inhibitor (dapagliflozin or empagliflozin). Baseline and 4-month follow-up data of 50 patients with type 2 diabetes who initiated SGLT2 inhibitor therapy were retrospectively obtained from medical records and analyzed. AEMD was measured using echocardiography and tissue Doppler. Inter-AEMD and intra-AEMD intervals were calculated. Left atrial volume (LAVOL) significantly decreased (45.23 ± 9.27 vs 42.21 ± 9.16; P < .001), while left intra-AEMD (19.58 ± 7.53 vs 16.76 ± 7.53; P <.001), right intra-AEMD (14.42 ± 5.81 vs 12.46 ± 8.05; P = .016), and inter-AEMD (34 ± 9.41 vs 29.22 ± 9.44; P < .001) were significantly reduced. Inter-AEMD change correlated with LAVOL, E/E′ ratio, body mass index, and mean blood pressure changes (all P <.05). In diabetic patients treated with SGLT2 inhibitors, AEMD reduction was observed after 4 months, with favorable metabolic and hemodynamic effects. These findings suggest that SGLT2 inhibitors may protect against AF by improving atrial electromechanical function.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90.
2.
ShahMSBrownleeM.Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016;118(11):1808-1829.
3.
KannelWBWolfPABenjaminEJLevyD.Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):1N-9N.
4.
BellDSHGoncalvesE.Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21(2):210-217.
5.
WangAGreenJBHalperinJLPicciniJPSr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107-1115.
6.
ChanYHChangGJLaiYJ, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18(1):125.
7.
PackerM.Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):121.
8.
GalloLAWrightEMVallonV.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12(2):78-89.
9.
AnkerSDButlerJFilippatosGS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial. Eur J Heart Fail. 2019;21(10):1279-1287.
10.
ZelnikerTAWiviottSDRazI, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.
11.
BöhmMSlawikJBrueckmannM, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020;22(1):126-135.
12.
PytkowskiMJankowskaAMaciagA, et al. Paroxysmal atrial fibrillation is associated with increased intra-atrial conduction delay. Europace. 2008;10(12):1415-1420.
13.
De VosCBWeijsBCrijnsHJ, et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart. 2009;95(10):835-840.
14.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S13-S27.
15.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S73-S85.
16.
LangRMBadanoLPMor-AviV, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-270.
17.
AslanMOksenDKaynakCOzudogruO.Impact of empagliflozin on left atrial mechanical and conduction functions in patients with type 2 diabetes mellitus. J Clin Ultrasound. 2023;51(3):398-404.
18.
ChenXChenMWangY, et al. Assessment of atrial electromechanical interval using echocardiography after catheter ablation in patients with persistent atrial fibrillation. J Biomed Res. 2016;30(6):483-489.
19.
OzturkSOzturkSErdemFH, et al. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure. J Interv Card Electrophysiol. 2016;46(3):253-258.
20.
MatsutaniDSakamotoMKayamaYTakedaNHoriuchiRUtsunomiyaK.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17:73.
21.
SacherFCorcuffJBSchraubP, et al. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions. Eur Heart J. 2008;29(10):1290-1295.
22.
HabibiJAroorARSowersJR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9.
23.
LiouYSYangFYChenHYJongGP.Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS One. 2018;13(4):e0197245.
24.
UsmanMSSiddiqiTJMemonMM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495-502.
25.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.
26.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
27.
NealBPerkovicVMahaffeyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
28.
LiWJChenXQXuLLLiYQLuoBH.SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19:130.
29.
SchottenUVerheuleSKirchhofPGoetteA.Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265-325.
30.
RajeevSPCuthbertsonDJWildingJP.Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016;18(2):125-134.
31.
ShaoQMengLLeeS, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18:165.
32.
MassonWLavalle-CoboANogueiraJP.Effect of SGLT2 inhibitors on epicardial adipose tissue: a meta-analysis. Cells. 2021;10:2150.
33.
GoudisCAVasileiadisIELiuT.Epicardial adipose tissue and atrial fibrillation: pathophysiological mechanisms, clinical implications, and potential therapies. Curr Med Res Opin. 2018;34:1933-1943.
34.
AsogluROzdemirMAladagNAsogluE.Evaluation of epicardial adipose tissue by echocardiography and its correlation with aortic velocity propagation and carotid intima-media thickness in patients with type 2 diabetes mellitus. An Acad Bras Cienc. 2020;92:e20191457.
35.
CosansuKYilmazS.Is epicardial fat thickness associated with acute ischemic stroke in patients with atrial fibrillation?J Stroke Cerebrovasc Dis. 2020;29:104900.
36.
YoshiokaHOhishiRHiroseY, et al. Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice. Obes Res Clin Pract. 2019;13:505-510.
37.
Diaz-RodriguezEAgraRMFernandezAL, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2018;114:336-346.
38.
VaziriSMLarsonMGBenjaminEJLevyD.Echocardiographic predictors of nonrheumatic atrial fibrillation: the Framingham Heart Study. Circulation. 1994;89:724-730.
39.
LiCDingXZhangJZhouCChenYRaoL.Does the E/e′ index predict the maintenance of sinus rhythm after catheter ablation of atrial fibrillation?Echocardiography. 2010;27:630-636.
40.
ChaoTFSungSHWangKL, et al. Associations between the atrial electromechanical interval, atrial remodelling and outcome of catheter ablation in paroxysmal atrial fibrillation. Heart. 2011;97:225-230.
41.
AtasHKepezAAtasDB, et al. Effects of diabetes mellitus on left atrial volume and functions in normotensive patients without symptomatic cardiovascular disease. J Diabetes Complications. 2014;28:858-862.
42.
DemirKAvciAKayaZ, et al. Assessment of atrial electromechanical delay and P-wave dispersion in patients with type 2 diabetes mellitus. J Cardiol. 2016;67:378-383.
43.
ZaccardiFWebbDRHtikeZZYoussefDKhuntiKDaviesMJ.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783-794.
44.
SogaFTanakaHTatsumiK, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:132.
45.
KarioKOkadaKKatoM, et al. 24-hour blood pressure–lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139:2089–2097.
46.
WangTJLarsonMGLevyD, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
47.
CuiQQZhangWWangH, et al. Assessment of atrial electromechanical coupling and influential factors in nonrheumatic paroxysmal atrial fibrillation. Clin Cardiol. 2008;31:74-78.
48.
YamanMArslanUBetonOAsarcikliLDAksakalADogduO.Atrial electromechanical coupling in patients with lichen planus. Korean Circ J. 2016;46:530-535.
49.
AltunBTasolarHGaziE, et al. Atrial electromechanical coupling intervals in pregnant subjects. Cardiovasc J Afr. 2014;25:15-20.
50.
AkyelAOksuzFKaradenizM, et al. Atrial electromechanical delay in type 2 diabetes mellitus. Wien Klin Wochenschr. 2014;126:101-105.
51.
ErmisNAcikgozNYasarE, et al. Evaluation of atrial conduction time by P-wave dispersion and tissue Doppler echocardiography in prehypertensive patients. Turk Kardiyol Dern Ars. 2010;38:525-530.
52.
SakaiTMiuraS.Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction: novel prospective cohort study. Circ Rep. 2019;1:286-295.
53.
AcarGAkcayASokmenA, et al. Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus. J Am Soc Echocardiogr. 2009;22:732-738.
